Meeting
2018 ASCO Annual Meeting
A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).
Authors
Anna M. Varghese
Memorial Sloan Kettering Cancer Center, New York, NY
Anna M. Varghese , Dana Backlund Cardin , Jonathan Hersch , Al Bowen Benson III, Howard S. Hochster , Robert E. Winkler , Fabio Benedetti , Kensuke Hamada , Jordan Berlin , Leonard B. Saltz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01916447
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3546)
DOI
10.1200/JCO.2018.36.15_suppl.3546
Abstract #
3546
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI.
First Author: Jakob Hagen Vasehus Schou
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 Gastrointestinal Cancers Symposium
Quadruplet regimen with capecitabine, irinotecan, oxaliplatin, and bevacizumab in chemo-naive patients with metastatic colorectal cancer: Results from the safety lead-in of QUATTRO-II study.
First Author: Hideaki Bando
Poster
2019 ASCO Annual Meeting
Trifluridine/tipiracil plus bevacizumab in elderly patients with previously untreated metastatic colorectal cancer (KSCC1602): A multicenter, phase II clinical trial.
First Author: Eiji Oki